The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).
 
Hiroyuki Arai
No Relationships to Disclose
 
Eisuke Inoue
Consulting or Advisory Role - Nippon Tect Systems; Pfizer
Speakers' Bureau - Bristol-Myers Squibb Japan; Eisai
 
Masanori Terashima
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Intuitive Surgical; Johnson & Johnson; Lilly; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Eishi Baba
Honoraria - Amgen; Bayer Yakuhin; Bristol Myers Squibb Foundation; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Tsumura & Co.; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca Japan; Daiichi Sankyo
Speakers' Bureau - Bristol Myers Squibb Foundation; Chugai Pharma; Daiichi Sankyo; Janssen; Lilly Japan; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Nobuhisa Matsuhashi
Honoraria - Amco; Asahi Kasei; Chugai Pharma; Covidien; Daiichi Sankyo; Gunze Medical; Johnson & Johnson; Kaken Pharmaceutical; Lilly Japan; Merck KGaA; Miyarisan pharmaceutical; MSD; Ono Pharmaceutical; Stryker; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.; Viatris; Yakult Honsha
Research Funding - Abbott (Inst); Asahi Kasei (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Corporation (Inst); EPS Holdings (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Kyowa Kirin (Inst); Lilly Japan (Inst); MSD K.K (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Shift Zero (Inst); Taiho Pharmaceutical (Inst); TERUMO (Inst); Tsumura & Co. (Inst)
 
Kei Muro
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; Ono Pharmaceutical; Solasia Pharma
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck KGaA (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Toshifumi Yamaguchi
Employment - Chugai Pharma; Ono Pharmaceutical; Yakult Honsha
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Wataru Ichikawa
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Kirin; Lilly; Merck; MSD K.K; Nihonkayaku; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Masashi Fujii
Travel, Accommodations, Expenses - Japan Clinical Cancer Research Organization
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Guardant Health; Incyte; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; Merck; MSD K.K
Research Funding - Chugai Pharma; Lilly Japan; Otsuka; Taiho Pharmaceutical; Takeda